One of the principal arguments against screening for prostate cancer during past evidence reviews by the UK NSC has always been the danger of overdiagnosis and overtreatment. This report, drawing on evidence gathered at the APPG’s meeting in April 2025 and supplemented with additional research, presents an updated consideration and perspective of how the risk of overdiagnosis and overtreatment of prostate cancer has been reduced, and makes several recommendations aimed at ensuring that these significant improvements to the diagnostic pathway are built upon further.

This report is supplemented by a separate Evidence Review, referenced as Appendix 1 in the report and accessible here.